Antibody-drug conjugates targeting PDL1 / B7H3, their preparation methods and applications

TW202641593APending Publication Date: 2026-10-16SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115100488
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-12-30
Filing Date
2026-01-06
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080876_001
    Figure TWG2TA001080876_001
  • Figure TWG2TA001080876_002
    Figure TWG2TA001080876_002
  • Figure TWG2TA001080876_003
    Figure TWG2TA001080876_003
Patent Text Reader

Abstract

This application relates to antibody-drug conjugates targeting PDL1 and B7H3, their preparation methods, and uses. The ADC of this application comprises a bispecific antibody conjugated to a cytotoxic drug, the antibody containing a domain specifically binding to PDL1 and a domain specifically binding to B7H3. This ADC and its drug can be used for the prevention and / or treatment and / or as adjuvant therapy for diseases (e.g., tumors) related to PDL1 and / or B7H3.
Need to check novelty before this filing date? Find Prior Art